CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.
Saved in:
| Title: | CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab. |
|---|---|
| Authors: | Chang XL; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Wu HL; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Webb GM; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Tiwary M; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Hughes C; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Reed JS; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Hwang J; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Waytashek C; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Boyle C; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Pessoa C; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Sylwester AW; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Morrow D; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Belica K; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Fischer M; Oregon National Primate Research Center, Oregon Health and Science University, Portland, OR, United States., Kelly S; CytoDyn Inc., Vancouver, WA, United States., Pourhassan N; CytoDyn Inc., Vancouver, WA, United States., Bochart RM; Oregon National Primate Research Center, Oregon Health and Science University, Portland, OR, United States., Smedley J; Oregon National Primate Research Center, Oregon Health and Science University, Portland, OR, United States., Recknor CP; CytoDyn Inc., Vancouver, WA, United States., Hansen SG; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States., Sacha JB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, OR, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2021 Nov 19; Vol. 12, pp. 794638. Date of Electronic Publication: 2021 Nov 19 (Print Publication: 2021). |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
